EHAB Stock Forecast 2025-2026
Distance to EHAB Price Targets
EHAB Price Momentum
10 Quality Stocks Worth Considering Now
Researching Enhabit (EHAB) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on EHAB and similar high-potential opportunities.
Latest EHAB Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, EHAB has a neutral consensus with a median price target of $9.00 (ranging from $8.50 to $10.00). Currently trading at $8.81, the median forecast implies a 2.2% upside. This outlook is supported by 1 Buy, 5 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Whit Mayo at Leerink Partners, suggesting a 3.5% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EHAB Analyst Ratings
EHAB Price Target Range
Latest EHAB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EHAB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 9, 2024 | Jefferies | Brian Tanquilut | Buy | Upgrade | $9.50 |
| Nov 19, 2024 | Leerink Partners | Market Perform | Reiterates | $0.00 | |
| Jun 27, 2024 | B of A Securities | Joanna Gajuk | Underperform | Maintains | $8.00 |
| May 14, 2024 | Leerink Partners | Whit Mayo | Market Perform | Upgrade | $8.50 |
| May 9, 2024 | Jefferies | Brian Tanquilut | Hold | Downgrade | $8.75 |
| Mar 11, 2024 | TD Cowen | Ryan Langston | Market Perform | Maintains | $11.00 |
| Mar 7, 2024 | Oppenheimer | Michael Wiederhorn | Perform | Maintains | $0.00 |
| Mar 7, 2024 | UBS | A.J. Rice | Neutral | Upgrade | $9.50 |
| Mar 6, 2024 | Jefferies | Brian Tanquilut | Buy | Maintains | $14.00 |
| Dec 12, 2023 | TD Cowen | Ryan Langston | Market Perform | Initiates | $12.00 |
| Aug 11, 2023 | Credit Suisse | Jonathan Yong | Neutral | Maintains | $12.00 |
| Jul 17, 2023 | Goldman Sachs | Jamie Perse | Neutral | Maintains | $13.00 |
| Mar 16, 2023 | Goldman Sachs | Jamie Perse | Neutral | Initiates | $15.00 |
| Feb 17, 2023 | Citigroup | Jason Cassorla | Neutral | Maintains | $18.00 |
| Feb 16, 2023 | Credit Suisse | Jonathan Yong | Neutral | Reiterates | $15.00 |
| Dec 13, 2022 | CJS Securities | Larry Solow | Market Perform | Initiates | $18.00 |
| Dec 8, 2022 | UBS | Andrew Mok | Sell | Initiates | $12.00 |
| Dec 6, 2022 | Stifel | Tao Qiu | Buy | Initiates | $17.00 |
| Nov 4, 2022 | Credit Suisse | Jonathan Yong | Neutral | Maintains | $15.00 |
| Oct 14, 2022 | Oppenheimer | Michael Wiederhorn | Perform | Initiates | $0.00 |
Enhabit Inc. (EHAB) Competitors
The following stocks are similar to Enhabit based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Enhabit Inc. (EHAB) Financial Data
Enhabit Inc. has a market capitalization of $449.78M with a P/E ratio of 0.0x. The company generates $1.03B in trailing twelve-month revenue with a -15.1% profit margin.
Revenue growth is -0.9% quarter-over-quarter, while maintaining an operating margin of +4.9% and return on equity of -24.5%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Enhabit Inc. (EHAB) Business Model
About Enhabit Inc.
Provides home health and hospice care services.
Enhabit Inc. generates revenue by offering home health and hospice care services to patients transitioning from hospital to home environments. The company focuses on delivering high-quality, patient-centered care, which not only enhances patient quality of life but also plays a crucial role in reducing hospital readmissions and improving overall healthcare outcomes.
Operating in multiple states across the U.S., Enhabit is committed to innovation and maintaining high care standards. The company's services are increasingly important as the population ages and the demand for personalized, in-home healthcare solutions rises.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
10,700
CEO
Ms. Barbara Ann Jacobsmeyer B.S., M.A., P.T.
Country
United States
IPO Year
2022
Website
www.ehab.comEnhabit Inc. (EHAB) Latest News & Analysis
Enhabit (EHAB) shares are gaining momentum, supported by positive earnings estimate revisions, suggesting potential continued upward movement.
Rising earnings estimates for Enhabit (EHAB) suggest improved financial performance, potentially driving stock prices up and attracting investor interest.
Enhabit, Inc. (NYSE: EHAB) has received Level 2 recognition as an Age-Friendly Health System from the IHI, highlighting its commitment to high-quality care for older adults.
Enhabit's Level 2 recognition enhances its reputation and credibility, potentially attracting more clients and partnerships, which can positively impact revenue and stock performance.
Enhabit, Inc. (NYSE: EHAB) will hold its Q4 2024 earnings call on March 6, 2025, at 10:00 AM ET, featuring key executives including the CEO and CFO.
Enhabit's Q4 2024 earnings call may reveal key financial performance and strategic insights, impacting stock valuation and investor sentiment. Market reactions depend on results and guidance provided.
Enhabit, Inc. (NYSE: EHAB) reported Q4 2024 results, noting stability in Medicare census and strategies for long-term growth in home health and hospice sectors.
Enhabit's strategic execution and stable Medicare census indicate potential for long-term growth, making it a more attractive investment in the home health and hospice sectors.
Enhabit (EHAB) reported quarterly earnings of $0.04 per share, below the Zacks Consensus Estimate of $0.05, and down from $0.06 per share in the same quarter last year.
Enhabit's earnings miss signals potential operational challenges, which may lead to negative investor sentiment and affect stock performance.
Enhabit, Inc. (NYSE: EHAB) will nominate Stephan Rodgers for election to its board at the 2025 annual meeting, bringing 25 years of relevant industry expertise.
The nomination of Stephan Rodgers to Enhabit's board signals potential strategic shifts and enhanced leadership, which could impact company performance and stock value.
Frequently Asked Questions About EHAB Stock
What is Enhabit Inc.'s (EHAB) stock forecast for 2025?
Based on our analysis of 13 Wall Street analysts, Enhabit Inc. (EHAB) has a median price target of $9.00. The highest price target is $10.00 and the lowest is $8.50.
Is EHAB stock a good investment in 2025?
According to current analyst ratings, EHAB has 1 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.81. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EHAB stock?
Wall Street analysts predict EHAB stock could reach $9.00 in the next 12 months. This represents a 2.2% increase from the current price of $8.81. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Enhabit Inc.'s business model?
Enhabit Inc. generates revenue by offering home health and hospice care services to patients transitioning from hospital to home environments. The company focuses on delivering high-quality, patient-centered care, which not only enhances patient quality of life but also plays a crucial role in reducing hospital readmissions and improving overall healthcare outcomes.
What is the highest forecasted price for EHAB Enhabit Inc.?
The highest price target for EHAB is $10.00 from at , which represents a 13.5% increase from the current price of $8.81.
What is the lowest forecasted price for EHAB Enhabit Inc.?
The lowest price target for EHAB is $8.50 from Whit Mayo at Leerink Partners, which represents a -3.5% decrease from the current price of $8.81.
What is the overall EHAB consensus from analysts for Enhabit Inc.?
The overall analyst consensus for EHAB is neutral. Out of 13 Wall Street analysts, 1 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $9.00.
How accurate are EHAB stock price projections?
Stock price projections, including those for Enhabit Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
